UPC CFI 2221/2026

Jun 22, 2026·EP3689365 Unitary patent · USE OF LONG-ACTING GLP-1 PEPTIDES

Case details: Status
Written Phase
Action
Revocation
Category
Main revocation action
Parties: Claimants
Sandoz AGOperating co.
Representatives
Jan van Dieck-Bird & Bird LLP
Respondents
Novo Nordisk A/SOperating co.
Representatives
Claire Phipps-Jones
Division: Milan CD
Judges: Andrea Postiglione
Anna-Lena Klein
Rudi Goedeweeck
Technology: Chemistry
Pharmaceuticals
Language: English
EPO Opposition: Wuesthoff & Wuesthoff Patentanwälte und Rechtsanwalt PartG mbBAdmissible2025-08-06
Generics (U.K.) LimitedAdmissible2025-08-07
Adalvo Ltd.Admissible2025-08-10
Dr. Reddy's Laboratories LimitedAdmissible2025-08-27
Galenicum Health S.L.U.Admissible2025-11-20
ZAKLADY FARMACEUTYCZNE POLPHARMA S.A.Admissible2025-12-24
Kraus & Lederer PartGmbBAdmissible2026-03-24
Maiwald GmbHAdmissible2026-04-09
Elkington and Fife LLPAdmissible2026-04-13
TEVA PHARMACEUTICAL INDUSTRIES, LTD.Admissible2026-04-19
DEVA HOLDING A.S.Admissible2026-04-28
SANDOZ AGAdmissible2026-04-28
Universal Farma, S.L.Admissible2026-05-06
Synthon BVAdmissible2026-05-05
Zentiva, k.s.Admissible2026-05-05
IP GRID EXPERT SRLAdmissible2026-05-05
Gedeon Richter Plc.Admissible2026-05-06
KRKA, d.d., Novo mestoAdmissible2026-05-06

How this compares

The court's record for this kind of case, counted in first-instance rulings. A figure in brackets is the number of rulings a rate rests on.

	Patent revoked	Median days to first decision
All UPC	37% (34/91)	124
Milan CD	Locked	Locked
Judge Andrea Postiglione	Locked	Locked
Judge Anna-Lena Klein	Locked	Locked
Judge Rudi Goedeweeck	Locked	Locked

At the UPC: Sandoz AG (1 case)·Novo Nordisk A/S (1 case)

Related cases

More cases: Milan CD·2026

Documents